CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: An in vivo study

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Shock, Anthony ^a   Burkly, Linda ^b   Wakefield, Ian ^a   Peters, Christopher ^a   Garber, Ellen ^b   Ferrant, Janine ^b   Taylor, Frederick R ^b   Su, Lihe ^b,d   Hsu, Yen Ming ^b,d   Hutto, David ^b,e   Amirkhosravi, Ali ^c   Meyer, Todd ^c   Francis, John ^c   Malcolm, Sarah ^a   Robinson, Martyn ^a   Brown, Derek ^a,f   Shaw, Stevan ^a   Foulkes, Roland ^a,g   Lawson, Alastair ^a   Harari, Olivier ^a   Bourne, Timothy ^a   Maloney, Alison ^a   Weir, Neil ^a   more..

^a UCB PHARMA   (Belgium)

^b BIOGEN   (United States)

^c FLORIDA HOSPITAL   (United States)

^d AB Biosciences Inc   (United States)

^e CHARLES RIVER LABORATORIES   (United States)

^f Cheylard Biosciences   (United Kingdom)

^g Hammel Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CDP 7657; FC RECEPTOR; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HU5C8; UNCLASSIFIED DRUG; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; TETANUS TOXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MACACA FASCICULARIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; RHESUS MONKEY; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOSIS; ANIMAL; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASES; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEW ZEALAND BLACK MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; AUTOIMMUNE DISEASES; CD40 LIGAND; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN FAB FRAGMENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACACA FASCICULARIS; MACACA MULATTA; MICE, INBRED NZB; POLYETHYLENE GLYCOLS; TETANUS TOXOID; THROMBOSIS;

EID: 84941259113     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0757-4     Document Type: Article

References (32)

1. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152-72.
2. Burkly LC. CD40 pathway blockade as an approach to immunotherapy. Adv Exp Med Biol. 2001;489:135-52.
3. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2-17.
4. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A. 1996;93:2499-504.
5. Gobburu JV, Tenhoor C, Rogge MC, Frazier DE, Thomas D, Benjamin C, et al. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys. J Pharmacol Exp Ther. 1998;286:925-30.
6. Xu H, Tadaki DK, Elster EA, Burkly LC, Berning JD, Cruzata F, et al. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation. 2002;74:940-3.
7. Davidson A, Wang X, Mihara M, Ramanujam M, Huang W, Schiffer L, et al. Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann NY Acad Sci. 2003;987:188-98.
8. Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity. 2004;37:457-64.
9. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-4.
10. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:896-9.
11. André P, Prasad KSS, Denis CV, He M, Papalia JM, Hynes RO, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002;8:247-52.
12. Langer F, Ingersoll SB, Amirkhosravi A, Meyer T, Siddiqui FA, Ahmad S, et al. The role of CD40 in CD40-L and antibody-mediated platelet activation. Thromb Haemost. 2005;93:1137-46.
13. Elzey BD, Ratliff TL, Sowa JM, Crist SA. Platelet CD40L at the interface of adaptive immunity. Thromb Res. 2011;127:180-3.
14. Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci. 2010;67:499-511.
15. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719-27.
16. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest. 2003;112:1506-20.
17. Huang W, Sinha J, Newman J, Reddy B, Budhai L, Furie R, et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 2002;46:1554-62.
18. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6:114.
19. Wakefield ID, Harari O, Hutto D, Burkly L, Ferrant J, Taylor F, et al. An assessment of the thromboembolic potential of CDP7657, a monovalent Fab' PEG anti-CD40L antibody, in rhesus macaques. Arthritis Rheum. 2010;62:1243.
20. Hsu Y-M, Su L. Platelet aggregation assays using a CD40L-binding agent. US patent No. 8409810 B2 (Issued Apr 2, 2013).
21. Robles-Carrillo L, Meyer T, Hatfield M, Desai H, Dávila M, Langer F, et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol. 2010;185:1577-83.
22. Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7:171-81.
23. Ferrant JL, Benjamin CD, Cutler AH, Kalled SL, Hsu Y-M, Garber EA, et al. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int Immunol. 2004;16:1583-94.
24. Quezada SA, Eckert M, Adeyi OA, Schned AR, Noelle RJ, Burns CM. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum. 2003;48:2541-54.
25. Nagelkerken L, Haspels I, van Rijs W, Blauw B, Ferrant JL, Hess DM, et al. FcR interactions do not play a major role in inhibition of experimental autoimmune encephalomyelitis by anti-CD154 monoclonal antibodies. J Immunol. 2004;173:993-9.
26. Pau E, Chang NH, Loh C, Lajoie G, Wither JE. Abrogation of pathogenic IgG autoantibody production in CD40L gene-deleted lupus-prone New Zealand Black mice. Clin Immunol. 2011;139:215-27.
27. Anderson CL, Chacko GW, Osborne JM, Brandt JT. The Fc receptor for immunoglobulin G (Fc gamma RII) on human platelets. Semin Thromb Hemost. 1995;21:1-9.
28. Xie JH, Yamniuk AP, Borowski V, Kuhn R, Susulic V, Rex-Rabe S, et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J Immunol. 2014;192:4083-92.
29. Lilbert J, Burnett R. Main vascular changes seen in the saline controls of continuous infusion studies in the Cynomolgus monkey over an eight-year period. Toxicol Pathol. 2003;31:273-80.
30. Gavins FN, Li G, Russell J, Perretti M, Granger DN. Microvascular thrombosis and CD40/CD40L signaling. J Thromb Haemost. 2011;9:574-81.
31. Crow AR, Leytin V, Starkey AF, Rand ML, Lazarus AH. CD154 (CD40 ligand)-deficient mice exhibit prolonged bleeding time and decreased shear-induced platelet aggregates. J Thromb Haemost. 2003;1:850-2.
32. Novo S, Basili S, Tantillo R, Falco A, Davì V, Novo G, et al. Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke. 2005;36:673-5.